Pavilion Payments and CasinoSoft Partner to Revolutionize Gaming Payments and Compliance
Together, Pavilion Payments and CasinoSoft are redefining what seamless, compliant, and guest-focused casino operations look like for the future of gaming.
Share
'We have put 20 years of our heart and soul into building the CasinoSoft brand and are thrilled with the many ways this acquisition moves us to the next level,' said Matt Montano, Principal and Owner of CasinoSoft. 'The success of our robust suite of AML/Title 31 and tax form products is evidenced by the longstanding partnerships we enjoy with our many satisfied customers throughout the industry.'
The new offering combines Pavilion Payments' seamless player funding and payment ecosystem with CasinoSoft's industry-leading compliance and automation software. The result is a powerful, vertically integrated platform that streamlines floor, cage, and slot operations, making them faster, easier, and more secure for casinos, route gaming as well as iGaming and sportsbook operators.
'CasinoSoft is the industry standard for AML/Title 31 compliance, automated tax forms, jackpot processing, and associated reporting services,' said Diallo Gordon, President of Pavilion Payments. 'With this acquisition, we plan to grow the broader Pavilion business with several new patents, innovative products, and transformative solutions that position us as the clear leader in fintech payments, cashless gaming, cage, and floor automation.'
For more than two decades, CasinoSoft has helped casinos streamline Title 31, AML, tax forms, and jackpot workflows, keeping operations audit-ready and freeing up staff to focus on the guest experience. By joining Pavilion Payments, CasinoSoft expands its ability to deliver end-to-end compliance and payment solutions within a single, connected system, reducing manual steps and increasing automation.
'At Pavilion Payments, we pride ourselves on offering our partners and customers a vibrant and diverse portfolio of products and services,' said Dan Connors, CEO of Pavilion Payments. 'The addition of CasinoSoft's products to our lineup furthers our delivery on that goal. We're delighted to add CasinoSoft to our team and look forward to delighting our customers with them.'
Together, Pavilion Payments and CasinoSoft are redefining what seamless, compliant, and guest-focused casino operations look like for the future of gaming.
About Pavilion Payments
Pavilion Payments enables the world's gaming entertainment leaders to create amazing consumer experiences and maximize spend across all their physical and digital properties. Pavilion Payments is the gaming industry's leading omnichannel payment solutions provider, offering integrated omnichannel and software solutions that enable flexible funding, play, and cash out. For more information, visit www.pavilionpayments.com.
About CasinoSoft
CasinoSoft is the leading provider of tech-forward compliance solutions for the casino and sports betting industry. Trusted nationwide, our powerful suite—including Title 31, TaxForms, and Automated Document Management modules—streamlines regulatory workflows, minimizes risk, and boosts operational efficiency. Designed with the end-user in mind, our solutions are intuitive, reliable, and built to keep properties ahead of evolving compliance demands. For more information, visit www.casinosoftusa.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Wikifarmer Launches UK Operations to Transform Olive Oil Sourcing for British Businesses
LONDON--(BUSINESS WIRE)--Wikifarmer, the Athens and Seville-based online agricultural marketplace, is launching UK operations to connect British businesses directly with Mediterranean olive oil producers. With Spanish olive oil prices down 53% year-over-year to €3.55/kg¹, this expansion targets Britain's £320 million olive oil market², projected to reach $1.55 billion by 2030⁶. "Our platform offers free access to quality European producers, with no hidden charges" Share Direct Access. Lower Costs. Greater Transparency. Wikifarmer's platform connects businesses directly with verified Mediterranean producers, eliminating intermediaries to provide transparent pricing, reliable logistics, and flexible credit terms with no subscription fees. The free-to-use model has connected over 7,000 buyers with 15,000 suppliers, facilitating millions in direct trade transactions. "The UK represents a massive opportunity to revolutionize how British businesses source Mediterranean olive oil," says Wikifarmer Co-Founder and CEO, Ilias Sousis. "We offer buyers direct access to quality European producers with the reliability and support they demand." Meeting UK Market Needs British businesses faced olive oil import price increases of 44% in 2024 while dealing with supply chain uncertainties. "Our platform offers free access to quality European producers, with no hidden charges," says Sam Frearson, UK Sales Manager. The UK's £128 billion food and agriculture sector¹¹ relies on traditional supply chains with multiple intermediaries, driving up costs and reducing transparency. Spain supplies 62% of UK olive oil imports, Italy 26%⁴, but most trade passes through costly middlemen. UK olive oil import values rose 31.7% to £333.2 million in 2023⁸, with olive oil comprising 87.1% of Britain's olive market⁷. Recent recovery in global production and a 13.9% drop in EU prices signal market stabilization¹⁰, making now ideal for direct sourcing. Expansion Plans The UK team will focus on onboarding buyers in wholesale, hospitality, retail, and food processing. This expansion advances Wikifarmer's vision to create a digital marketplace connecting farmers directly with buyers, eliminating intermediaries for fair, transparent trade. The company plans further European expansion throughout 2025. About Wikifarmer Wikifarmer ( combines the world's largest agricultural knowledge library with an online B2B marketplace. With over 20,000 direct transactions, Wikifarmer helps businesses reduce costs and supports farmers' profitability.
Business Wire
an hour ago
- Business Wire
JR-PLUS & Cinnamoroll Collaborative Campaign Starts!
NAGOYA, Japan & TOKYO--(BUSINESS WIRE)--During the period from Tuesday, August 19, to Monday, September 8, 2025, JR Central Retailing Plus Co., Ltd. stores will hold a Cinnamoroll Collaborative Campaign in conjunction with Cinnamoroll, the popular character from Sanrio Company, Ltd. In this campaign, stores will sell station lunchboxes (ekiben) and original goods only available through this collaboration, created with the concept of 'Cinnamoroll and his friends are helping out at station shops!' Two types of original 'KAWAII' illustrations only available during this campaign Uniform version for JR Central, which runs the Tokaido Shinkansen Uniform version as a chef, which is Cinnamoroll's 'dream' Sale of original collaborative goods Original goods with designs created specifically for this fair will be on sale. Ball chain mascot JR Central uniform ver.: 2,618 yen Ball chain mascot cafe uniform ver.: 2,618 yen Face coin purse: 1,540 yen Tote bag: 2,530 yen Drawstring bag 2P: 1,408 yen Three-pocket clear pouch: 2,178 yen Onigiri case (with carabiner): 2,178 yen Acrylic key chains (6 types): 770 yen each (4,620 yen for a box) Button badges (10 types): 550 yen each (5,500 yen for a box) Sale of original ekiben created in collaboration with Cinnamoroll Cinnamoroll Ekiben: 1,580 yen Other limited-offer collaborative package onigiri, sandwiches, and sweets will also be offered. Cinnamoroll Collaborative Campaign overview - Campaign dates: Tuesday, August 19, 2025 to Monday, September 8, 2025 - Campaign locations: Plusta, Bellmart, Grand Kiosk, Gift Kiosk, Precious Deli & Gift, etc. at Tokyo Station, Shinagawa Station, Shizuoka Station, Nagoya Station, Kyoto Station, Shin-Osaka Station, and others. See details here © 2025 Sanrio Co., Ltd. Approval No. L661918 *All prices include consumption tax. *All images are for illustrative purposes.
Business Wire
an hour ago
- Business Wire
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the completion of patient enrollment in the second cohort of its Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. Recruitment of the second cohort, composed of three patients aged between 6 and 31 months, was recently completed with the injection of the third patient. Patients in this second cohort were administered, unilaterally, a dose of d4.5 E 11 vg/vector/ear of SENS-501 which was higher than the dose in the 1 st cohort (1.5 E 11 vg/vector/ear). For all patients treated in the first and second cohorts, the surgical procedure was well tolerated: the intra-cochlear administration of the gene therapy product was uneventful. No serious adverse events and no serious side effects were reported. Early signs of hearing improvement have been observed in Patient 3, aged 11 months at the time of injection, three months after receiving the low dose. Nawal Ouzren, Chief Executive Officer of Sensorion, commented: "The completion of patient enrollment in the second cohort in Audiogene is an important milestone as it enables us to attest to the safety of the surgical approach, as no serious adverse events have been observed in all six patients injected, and of the good tolerability of SENS-501 to date. I look forward to advancing this innovative and unique program to its next steps, notably with the planned Data Monitoring Committee meeting, and to providing an update as soon as the data have sufficiently matured. On behalf of my colleagues, I would like to extend gratitude to the patients' families for their trust, as well as all the healthcare professionals involved in this clinical trial.' Professor Natalie Loundon, M.D., Director of the Center for Research in Pediatric Audiology, Pediatric Otolaryngologist and Head and Neck Surgeon, Necker Enfants Malades, AP-HP, in Paris, France, Principal Investigator of the Audiogene clinical study, added: 'I am thrilled we have successfully completed the patient enrollment of the second Cohort in Audiogene's Phase 1/2 gene therapy trial. The good tolerability of patients to SENS-501 so far and the preliminary positive data from the first cohort are very encouraging first steps for the continuation of this trial that has the potential to address a global significant unmet medical need. Once again, I would like to thank the patients' families for their trust.' Audiogene ( ID: NCT06370351) is the first gene therapy clinical trial addressing a unique homogeneous population of infants and toddlers (aged 6 to 31 months and naive of cochlear implants at the time of the injection, as per study protocol). Audiogene's clinical trial design has been intended to assess SENS-501 gene therapy product's safety and tolerability as well as its capacity not only to restore hearing but also to allow the infants and toddlers to acquire and develop normal speech. Moreover, Audiogene aims to evaluate the usability, the clinical and the technical performances of the injection system in development. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l'Audition. The project is partially financed by the French National Research Agency, through the 'investing for the future' program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About the Audiogene Trial Audiogene aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
